Targeting kupffer cells with antisense oligonucleotides

Frontiers in Bioscience - Landmark

Volumn 7, Issue 5, 2002, Pages 223-233

  Ponnappa, Biddanda C ^a   Israel, Yedy ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Antisense; Cytokine; Delivery; Inflammation; Kupffer Cell; Liposome; Liver; Oligonucleotide; PH sensitive; Review; TNF alpha

Indexed keywords

COMPLEMENTARY DNA; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CYTOLOGY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; GENETICS; HUMAN; KUPFFER CELL; LIVER DISEASE; METABOLISM; METHODOLOGY; NUCLEOTIDE SEQUENCE; REVIEW;

ANIMALS; BASE SEQUENCE; DNA, ANTISENSE; DRUG DELIVERY SYSTEMS; HUMANS; KUPFFER CELLS; LIPOSOMES; LIVER DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85052012370     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/a918     Document Type: Article

References (85)

1. Golde D.W. & J. C. Gasson: In: Inflammation. Basic Principles & Clinical Correlates. Eds: Gallin, J.I., I. M. Goldstein & R.Snyderman, Raven Press, New York. pp 253-264 (1988)
2. Alterman K: In: Kupffer cells and other sinusoidal cells. Eds: Wisse, E & D. L. Knook Elsevier/North Holland, Biomedical Press, Amsterdam, New York, pp-3-20 (1977)
3. Decker, K: Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem 192, 245-261 (1990)
4. Badwey J. A & M. L. Karnovsky: Active oxygen species and functions of phagocytic leukocytes. Ann Rev Biochem 49, 695-726 (1980)
5. Akerman P, P. Cote, S. Q. Yang, C. McClain, S. Nelson, G. J. Bagby & A. M. Diehl: Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Amer J Physiol 263 (4 Pt 1), G579-585 (1992)
6. Takeishi T, K. Hirano, T. Kobayashi, G. Hasegawa, K. Hatakeyama & M. Naito: The role of Kupffer cells in liver regeneration. Archives of Histol & Cytol 62, 413-422 (1999)
7. Hoffmann R, M. Grew, H-C. Estler, A. Schulze-Specking & K. Decker: Regulation of tumor necrosis factor-α mRNA synthesizing cells in rat liver during experimental endotoxemia. J Hepatology 20, 122-128 (1994)
8. Ertel W, M. Morrison, A. Ayala & I. Chaudry: Hypoxemia in the absence of blood loss or significant hypotension causes inflammatory cytokine release. Amer J Physiol 269 (Regulatory Integrative Comp Physiol), R160-R166 (1995)
9. Knolle P, H. Lohr, U. Treichel, H-P. Diens, A. Lohse, J. Schlaack, & G. Gerken: Parenchymal and nonparenchymal liver cell and their interaction in the local immune response. Z. Gasteroenterol 33: 613-620 (1995)
10. Bautista A. P & J. J. Spitzer: Role of Kupffer cells in ethanol-induced oxidative stress in the liver. Front Biosci 4, d589-595 (1999)
11. Bautista A. P, N. Skrepnik, M. R. Niesman & G. J. Bagby: Elimination of macrophages by liposome-encapsulated dichloromethylene diphosphonate supresses the endotoxin-induced priming of Kupffer cells. J Leukocyte Biol 55, 321-327 (1994)
12. Adachi Y, B. U. Bradford, W. Gao, H. Bojes, R. G. Thurman: Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 20, 453-460 (1994)
13. Laskin D. L, C. R. Gardner, V. F. Price & D. J. Jollow: Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology 21, 1045-1050 (1995)
14. Wheeler M. D, M. Nagami, B. U. Bradford, T. Uesugi, R. P. Mason, H. D. Connor, A. Dikalova, M. Kadiiska & R. G. Thurman: Overexpression of manganese superoxide dismutase prevents alcohol-induced liver injury in the rat. J. Biol Chem 276, 36664-36672 (2001)
15. Kono H, I. Rusyn, M. Yin, E. Gabele, S. Yamashina, A. Dikalova, M. B. Kadiiska, H. D. Connor, R. P. Mason, B. H. Segal, B. U. Bradford, S. M. Holland & R. G. Thurman: NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J. Clin Invest 106, 867-872 (2000)
16. Nakae D, K. Yamamoto, H. Yoshiji, T. Kinugasa, H. Maruyama, J. L. Farber & Y. Konishi: Liposome-encapsulated superoxide dismutase prevents liver necrosis induced by acetaminophen. Amer J Pathol 136, 787-795 (1990)
17. Wu J & M. A. Zern: NF-Kappa B, liposomes and pathogenesis of hepatic injury and fibrosis. Front Biosci 4, d520-527 (1999)
18. Eigler A, B. Sinha, G. Hartman & S. Endres: Taming TNF: strategies to restrain this proinflammatory cytokine. Immunology Today, 18, 487-492 (1997)
19. Iimuro Y, R. M. Galluchi, M. I. Luster, H. Kono & R. G. Thurman: Antibodies to tumor necrosis factor alfa attenuates hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 26, 1530-1537 (1997)
20. Wanner G. A, P. E. M. Muller, W. Ertel, M. Bauer, M. D. Menger & K. Messmer: Differential effect of anti-TNF-alpha antibody on proinfalmmatory cytokine release by Kupffer cells following liver ischemia and reperfusion. Shock 11, 391-395 (1999)
21. Tu G-c, Q-na Cao, F. Zhou & Y. Israel: Tetranucleotide GGGA motif in primary RNA transcripts. J. Biol Chem 273, 25125-25131 (1998)
22. Hu R-H & S-H Chu: Suppression of tumor necrosis factor secretion from white blood cells by synthetic antisense phosphorothioate oligodeoxynucleotides. Int J Immunopharmacol 22, 445-452 (2000).
23. Zamecnik P & M. L. Stephenson: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natnl. Acad. Sci (USA) 75, 280-284 (1978)
24. Giles R. V, D. G. Spiller & D. M. Tidd: Detection of ribonuclease H-directed mRNA generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res Dev 5, 23-31 (1995)
25. Crooke S. T: Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1489, 31-44 (1999)
26. Crooke S. T, Ed: Antisense Research and Application, Springer, New York, 1998
27. Eckstein, F: Nucleoside phosphorothioates. Annu Rev Biochem 54, 367-402 (1985)
28. Agrawal S. J. Temsamani & J. Y. Tang: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88, 7595-7599 (1991)
29. Cossum P. A, H. Sasmor, D. Dellinger, L. Truong, L. Cummins, S.R. Owens, P.M. Markham, J. P. Shea & S. Crooke: Disposition of 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267, 1181-1190 (1993)
30. Zhang R, R. P. Iyer, D. Yu, W. Tan, X. Zhang, Z. Lu, H. Zhao & S. Agrawal: Pharmacokinetics and tissue distribution of chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J Pharmacol Exp Ther 278, 971-979 (1996)
31. Goodchild J, B. Kim & P. C. Zamecnik: The clearance and degradation of oligodeoxynucleotide following intravenous injection into rabbits. Antisense Res Dev 1, 153-160 (1991)
32. Stein C. A: How to design an antisense oligonucleotide experiment: a consensus approach. Antisense Nucleic Acid Drug Dev 8, 129-132 (1998)
33. Chiang M. Y, H. Chan, M. A. Zounes, S. M. Frier, W. F. Lima, & C. F. Bennett: Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 266, 18162-18171, (1991)
34. Stull R. A, L. A. Taylor, & F. C. Szoka Jr.: Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices. Nucleic Acid Res. 20, 3501-3508 (1992)
35. Krieg A. M: Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489, 107-116 (1999)
36. Fenster S. D, R. Wagner, B. C. Froehler & D. J. Chin: Inhibition of human immunedeficiency virus type-1 env expression by C-5 propyne oligonucleotides specific for rev response element stem loop V. Biochemistry 33, 8391-8398 (1994)
37. Garcia-Chaumont C, O. Seksek, J. Grzybowska, E. Borowski & J. Bolard: Delivery systems for antisense oligonucleotides. Pharmacol and Ther 87, 255-277 (2000)
38. Burch R. M & L. C. Mahan: Oligonucleotides antisense to the interleukin-1 receptor mRNA block the effects of interleukin-1 in cultured murine and human fibroblasts and in mice. J Clin Invest 88, 1190-1196 (1991)
39. Loke S. L, C. A. Stein, X. Zang, M. Avigan, J. Cohen & L.M Neckers: Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis. Curr Topc Microbiol Immunol 141, 282-289 (1988)
40. Thierry A. R & A. Dritchilo: Intracellular availability of unmodified phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 20, 5691-5698 (1992)
41. Ellens H, B. Bentz, & F. C. Szoka: pH-induced destabilization of phosphatidylethanolamine-containing liposomes: Role of bilayer contact. Biochemistry 23, 1532-1538 (1984)
42. Hazemoto N, M. Harada, S. Suzuki, F. Kaiho, M. Haga & Y. Kato: Effect of phosphatidylcholine and cholesterol on pH-sensitive liposomes. Chem Pharm Bull 41, 1003-1006 (1993)
43. Connor J. & L. Huang: Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive immunoliposomes. J Cell Biol 101, 582-589 (1985)
44. Straubinger, R.M: pH-sensitive liposomes for delivery of macromolecules into cytoplasm of cultured cells. Methods in Enzymol 221, 361-376 (1993)
45. Tachibana R, H. Harashima, M. Shono, M. Azumano, M. Niwa, S. Futaki & H. Kiwada: Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: Qualitative and quantitative evaluation of intracellular trafficking. Biochem Biophys Res Comm 251, 538-544 (1998)
46. Ponnappa B. C, I. Dey, G-c Tu, F. Zhao, M. Aini, Q-na Cao & Y. Israel: In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats. J. Pharmcol Exp Ther 297, 1129-1136 (2001)
47. Szoka F & D. Papahadjopoulos: Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci (USA) 75: 4194-4198 (1978)
48. Felgner P. L: Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides. Adv Drug Deliver Rev 5, 163-187 (1990)
49. Bennett C. F, M. Y. Chiang, H. Chan, J. E. Shoemaker & C. K. Mirabelli:. Cationic lipids enhance uptake and activity of phosphorothioate antisense oligonucleotides. Molecular Pharmacol 41, 1023-1033 (1992)
50. Bennett C. F, D. Mirejovsky, R. M. Crooke, Y. J. Tsai, J. Felgner, C. N. Sridar, C. J. Wheeler & P. L. Felgner: Structural requirements for cationic lipid mediated phosphorothioate oligonucleotide delivery to cells in culture. J. Drug Target 5, 149-162 (1998)
51. Senior J. H, K. R. Trimble & R. Maskiewicz: Interaction of positively charged liposomes with blood: implications for their application in vivo. Biochim Biophys Acta 1070, 173-179 (1991)
52. Lewis J. G, K-Y Lin, A. Kothavale, W. M. Flanagan, M. D. Matteucci, R. B. DePrince, R. A. J. Mook, R. Wayne Hendren, & R. W. Wagner: A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl Acad Sci (USA), 93, 3176-3181 (1996)
53. Chaudhuri G: Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Biochem Pharmacol 53, 385-391 (1997)
54. Citro G, D. Perroti, C. Cucco, I. D’Agnano, A. Sacchi, G. Zupi, and B. Calabretta: Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligonucleotides. Proc. Natl Acad Sci (USA) 89, 7031-7035 (1992)
55. Boussif O, F. Lezoualc’h, M. A. Zanta, M. J. Mergny, D. Scherman, B. Demeneix, & J-P Behr: A versatile versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad Sci USA 92, 7297-7301 (1995)
56. Hughes J. A, A. I. Aronsohn, A. V. Avrutskaya, & R. L. Juliano: Evaluation of adjuvants that enhance the effectiveness of antisense oligonucleotides. Pharm Res, 13, 404-410 (1996)
57. Stahl P, P. H. Schlesinger, E. Sigardson, J. S. Rodman & Y. C. Lee: Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages: characterization and evidence for receptor recycling. Cell 19, 207-217 (1980)
58. Liang W, X. Shi, D. Deshpande, C. J. Malanga & Y. Rojanasakul: Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim Biophys Acta 1279, 227-234 (1996) 59. Agrawal S & Q. Zhao: Antisense therapeutics. Curr Opin Chem Biol 2, 519-528 (1998)
59. Bilbao G, J. L. Contreras & D. T. Curiel: Advances in cancer gene therapy. Expert Opin Ther Patents 9, 711-735 (1999)
60. Crook S. T & C. F. Bennett: Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 36, 107-129 (1996)
61. Feld A. K: Viral targets for antisense oligonucleotides: a mini review. Antiviral Res 37, 67-81 (1998)
62. Ho P. T. C & D. R. Parkinson: Antisense oligonucleotide as therapeutics for malignant diseases. Semin Oncol 24, 187-202 (1997)
63. Ma L & F. Calvo: Recent status of the antisense oligonucleotide approaches in oncology. Fundam Clin Pharmacol 10, 97-115 (1996)
64. Agrawal S & S. T. Crooke (Eds): Antisense Research and Application. Handbook of Experimental Pharmacology. Springer; Berlin, New York (1998)
65. Stein C. A & A. M. Krieg (Eds) Applied Antisense Oligonucleotide Technology. Wiley-Liss, New York (1998)
66. Bennett C. F, J. E. Zukerman, D. Kornbrust, H. Sasmor, J. M. Leeds, and S. T. Crooke: Pharmacokinetics in mice of a 3H-labeled phosphorothioate oligonucleotide formulated in the presence and absence of cationic lipid. J. Controlled Release 41, 121-130 (1996)
67. Bijsterbosch M. K, M. Manoharan, E. K. Rump, R. L. A. De Vrueh, R. van Veghel, K. L. Tivel, E. A. L. Biessen, C. F. Bennett, P. D. Cook, & T. J. C. van Berkel: In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acid Res 25, 3290-3296 (1997)
68. Stein C. A: Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Biochim Biophys Acta 1489, 45-52 (1999)
69. Ponnappa B. C, I. Dey, G-c. Tu, F. Zhou, E. Garver, Q-na Cao & Y. Israel: In vivo delivery of antisense oligodeoxynucleotides into rat Kupffer cells. J. Liposome Res 8, 521-535 (1998)
70. Bennett, C.F: Use of cationic lipid complexes for antisense oligonucleotide delivery. In: Applied Antisense Oligonucleotide Technology. Eds: C.A. Stein & A.M. Krieg, Wiley-Liss, New York, pp 129-145 (1998)
71. Litzinger D. C, J. M. Brown, I. Wala, S. A. Kaufman, G. Y. Van, C. L. Farrell, & D. Collins: Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta, 1281, 139-149 (1996)
72. Alino S. F, J. Crespo, G. Tarrason, C. Blaya, J. Adan, E. Escrig, M. Benet, A. Crespo & J. Piulats: Oligonucleotide-entrapped immunoliposome delivered by mini-osmotic pump improves the survival of SCID mice bearing human leukemia. Tumor Target 4, 20-28 (1999)
73. Agrawal S & R. Zhang: Pharmacokinetics of oligonucleotides. Ciba Foundation Symposium Wiley, Chichester 209, 60-78 (1997)
74. Rifai A, W. Brysch, K. Fadden, J. Clark & K-H. Schlingensiepen: Clearance kinetics, biodistribution and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am J Pathol 149, 717-725 (1996)
75. Bissen E. A. L, H. Vietsch, J. Kuiper, M. K. Bijsterbosch & T. J. C. van Berkel: Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol 53, 262-269 (1998)
76. Bijsterbosch M. K, M. Manoharan, R. Dorland, I. H. E. Waarlo, E. A. L. Bissen & T. J. C. van Berkel: Delivery of cholesteryl-conjugated phosphorothioate oligodeoxynucleotides to Kupffer cells by lactosylated low-density lipoprotein. Biochem Pharmacol 62, 627-633 (2001)
77. Bijsterbosch M. K, G. J. Ziere & T. J. Van Berkel: Lactosylated low density lipoprotein: a potential carrier for the site-specific delivery of drugs to Kupffer cells. Mol Pharmacol 36, 484-489 (1989)
78. Tschaikowsky K, & J. D. Brain: Staurosporine encapsulated into pH-sensitive liposomes reduces TNF production and increases survival in rat endotoxin shock. Shock 1, 401-407 (1994)
79. Hiraoka E, T. Naonami, T. Kurokawa, H. Kobayashi & H. Takagi: The role of the spleen in endotoxin-induced liver injury. Liver 15, 35-38 (1995)
80. Ponnappa B. C, F. Zhou, M. Aini, G. Tu, Q-na Cao, Y. Israel & R. Rubin: In vivo delivery of antisense oligonucleotide against TNF-alpha mRNA prevents lipopolysaccharide-induced liver damage in ethanol-fed rats (Abstract). Hepatology 34, 463A (2001)
81. Zhang X, L. Collins & J. W. Fabre: A powerful cooperative interaction between a fusogenic peptide and lipofectamine for the enhancement of receptor-targeted, non-viral gene delivery via integrin receptors. J Gene Med 3, 560-568 (2001)
82. Freulon I, A. C. Roche, M. Monsigny, R. Mayer: Delivery of oligonucleotides into mammalian cells by anionic peptides: comparison between monomeric and dimeric peptides. Biochem J 354 (Pt 3), 671-679.
83. Smith C. C, M. Kulka & L. Aurealian: Modified adenovirus penton base protein (UTARVE) as a non-replicating vector for delivery of antisense oligonucleotides with antiviral and/or antineoplastic activity. Int J Oncol 17, 841-50 (2000)
84. Adah S. A, S. F. Bayly, H. Cramer, R. H. Silverman & P. F. Torrence: Chemistry and biochemistry of 2',5'-oligoadenylate-based antisense strategy. Curr Med Chem 8,1189-1212 (2001)
85. Caplen N.J: A new approach to the inhibition of gene expression. Trends Biotechnol 20, 49-51 (2002)